{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:33:20Z","timestamp":1790609600757,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clinthera.2019.11.009","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:53:04Z","timestamp":1578617584000},"page":"77-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy"],"prefix":"10.1016","volume":"42","author":[{"given":"Tingjian","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallik","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy R.","family":"Houle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi C.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian H.","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.11.009_bib1","author":"The National Institute of Mental Health"},{"key":"10.1016\/j.clinthera.2019.11.009_bib2","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The economic burden of schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J\u00a0Clin Psychiatr"},{"key":"10.1016\/j.clinthera.2019.11.009_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-10-2","article-title":"The cost of relapse and the predictors of relapse in the treatment of schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"2 Suppl","key":"10.1016\/j.clinthera.2019.11.009_bib4","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.clinthera.2019.11.009_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/CEOR.S160252","article-title":"Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA","volume":"10","author":"Aigbogun","year":"2018","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.clinthera.2019.11.009_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-244X-12-99","article-title":"Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study","volume":"12","author":"Berger","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.clinthera.2019.11.009_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1590\/S1516-44462007000300004","article-title":"Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine","volume":"29","author":"de Castro","year":"2007","journal-title":"Braz J Psychiatry"},{"key":"10.1016\/j.clinthera.2019.11.009_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s12325-018-0785-y","article-title":"Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data","volume":"35","author":"Yan","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.11.009_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clinthera.2019.11.009_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2019.11.009_bib11","series-title":"HCUP chronic condition indicator. Healthcare cost and utilization Project (HCUP)","year":"2015"},{"key":"10.1016\/j.clinthera.2019.11.009_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.clinthera.2019.11.009_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J\u00a0Clin Psychiatr"},{"key":"10.1016\/j.clinthera.2019.11.009_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-0500-2-6","article-title":"Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia","volume":"2","author":"Ascher-Svanum","year":"2009","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clinthera.2019.11.009_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.clinthera.2019.11.009_bib16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ps.2010.61.12.1239","article-title":"Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics","volume":"61","author":"Lang","year":"2010","journal-title":"Psychiatr Serv Wash DC"},{"key":"10.1016\/j.clinthera.2019.11.009_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr Serv Wash DC"},{"key":"10.1016\/j.clinthera.2019.11.009_bib18","series-title":"Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence","author":"Nau","year":"2012"},{"key":"10.1016\/j.clinthera.2019.11.009_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"8 Suppl","key":"10.1016\/j.clinthera.2019.11.009_bib20","first-page":"S254","article-title":"Impact of atypical antipsychotics on outcomes of care in schizophrenia","volume":"11","author":"Joyce","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2019.11.009_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.11.009_bib22","first-page":"418","article-title":"Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder","volume":"41","author":"Eaves","year":"2016","journal-title":"P\u00a0T Peer-rev J Formul Manag"},{"key":"10.1016\/j.clinthera.2019.11.009_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2045125315614739","article-title":"Brexpiprazole: so far so good","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.clinthera.2019.11.009_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.9740\/mhc.2017.09.207","article-title":"Brexpiprazole: a review of a new treatment option for schizophrenia and major depressive disorder","volume":"7","author":"Diefenderfer","year":"2017","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.clinthera.2019.11.009_bib25","first-page":"1641","article-title":"Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression","volume":"10","author":"Bruijnzeel","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2019.11.009_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/YIC.0000000000000123","article-title":"The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study","volume":"31","author":"Citrome","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2019.11.009_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11414-013-9329-z","article-title":"Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia","volume":"40","author":"Lin","year":"2013","journal-title":"J\u00a0Behav Health Serv Res"},{"key":"10.1016\/j.clinthera.2019.11.009_bib28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","article-title":"Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics","volume":"35","author":"Shah","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.11.009_bib29","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2017.08.008","article-title":"Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics","volume":"39","author":"Pilon","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.11.009_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212267","article-title":"Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients","volume":"4","author":"Kamat","year":"2015","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2019.11.009_bib31","first-page":"357","article-title":"Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics","volume":"18","author":"Baser","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2019.11.009_bib32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:26Z","timestamp":1758963146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0149291819305703"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}